Bayer-18
| Code | Size | Price |
|---|
| SYN-1130-M100 | 100 mg | Enquire |
Quantity:
| SYN-1130-M050 | 50 mg | Enquire |
Quantity:
| SYN-1130-M001 | 1 mg | £233.00 |
Quantity:
| SYN-1130-M005 | 5 mg | £578.00 |
Quantity:
| SYN-1130-M010 | 10 mg | £824.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
Bayer18
Appearance:
Solid.
CAS:
1251752-12-1
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Hazards:
H302, H317
InChi:
InChI=1S/C19H27FN6O2/c1-18(2,3)26-17(28)23-13-8-6-7-12(9-13)22-16-21-10-14(20)15(24-16)25-19(4,5)11-27/h6-10,27H,11H2,1-5H3,(H2,23,26,28)(H2,21,22,24,25)
InChiKey:
DYNMZYFOSRSMAC-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 1251752-12-1. Formula: C19H27FN6O2. MW: 390.5. Bayer-18 is a selective TYK2 inhibitor, with an IC(50) of 18.7nM on TYK2 as measured by TYK2 HTRF assays. The compound shows 1000 fold selectivity against JAK2, CDK and KDR kinases in similar HTRF assays.
Molecular Formula:
C19H27FN6O2
Molecular Weight:
390.5
Package Type:
Plastic Vial
Precautions:
P264, P270, P301, P312, P330, P501, P261, P272, P280, P302, P352, P333, P313, P321, P363, P501
Product Description:
Bayer-18 is a selective TYK2 inhibitor, with an IC(50) of 18.7nM on TYK2 as measured by TYK2 HTRF assays. The compound shows 1000 fold selectivity against JAK2, CDK and KDR kinases in similar HTRF assays.
Purity:
>95%
Signal word:
Warning
Solubility Chemicals:
Soluble in DMSO.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
New phenyl-pyrimidin-2-yl-amine compounds are tyrosine kinase 2 inhibitors useful for treating E.G. rheumatoid arthritis, Crohn's disease, asthma, multiple sclerosis, adult respiratory distress syndrome, allergic alveolitis and uveitis: B. Buchmann, et al.; DE102009015070 (2010)
Related Products
| Product Name | Product Code | Supplier | BBT594 | SYN-1225 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|